2024 Laboratory Reimbursement Trends and What to Expect in 2025
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond
In last month’s key cases, Illumina and Guardant seek to dismiss lawsuit related to trade secrets and breach of contract.
A strategic partnership with Google enables more accurate whole genome sequencing with machine learning.
More multiplex COVID-19 combination tests emerge from premarket authorization pipeline.
Seven months into the year, there were already four reported deals valued at over $1 billion in 2023, as many as in all of 2022.
Proposed rule would require businesses to undergo even more stringent review to secure regulatory approval for such deals.
Recent advisory opinion offers insight on how healthcare providers may want to structure arrangements involving online directories.
Inadequate CMS oversight resulted in $888.2 million in improper payments for the highest reimbursing molecular pathology genetic tests, report says.
The proposed PFS rule also includes other changes that will affect physician, lab, and other reimbursements in 2024 and beyond.
Recently proposed rule seems too stringent to reduce the lag between FDA approval and Medicare coverage.
Centers for Medicare & Medicaid Services proposes TCET pathway to expedite Medicare Coverage of newly approved breakthrough devices.